Biomarkers for deciding a medication in a myocardial infarction patient
Posted in the Cardiology Forum
#1 Sep 2, 2011
This US patent application describes a method of deciding which treatment or combination of treatments is to be applied in a remodeling process of a patient after a myocardial infarction. The method consist of determining an amount of a natriuretic peptide, a cardiac troponin, and an inflammatory marker in a sample from the patient, and initiating a remodeling in the subject, wherein a medication to be applied in the remodeling is selected according to the level of the peptide, troponin, and marker determined. An amount of NT-proBNP of 300 pg/ml is indicative of administering a medication selected from the group consisting of beta blockers, natriuretics, loop diuretics, nitrates, and positive inotropic agents. An amount of GDF-15 800 pg/ml is indicative of administering a medication selected from the group consisting of ACE inhibitors, angiotensin receptor antagonists, statins; NSAIDS, and selective COX-2 inhibitors. An amount of CRP-15>3 pg/ml is indicative of administering a medication selected from the group consisting of statins. An amount of osteopontin >500 pg/ml is indicative of administering a medication selected from the group consisting of anti-inflammatory drugs, angiotensin receptor antagonists, and aldosterone antagonists. News link: http://www.sciclips.com/sciclips/biomarker-ne...
Add your comments below
|Multiple foci of Intraparenchymal extravasated||9 hr||jennie||1|
|Ten transgender truths for legislators and conc...||Jun '17||TerriB1||1|
|How Trump was going to end the Cold War in the ...||Jun '17||arrron7788||2|
|heart rhythm off. skips a beat and speeds up fo... (Aug '08)||Feb '17||Dale1065||112|
|Non-Specific ST Changes||Feb '17||PVCJCC87||1|
|Interpreting results of nuclear stress test (Jan '11)||Jan '17||Drake||14|
|Risks of heart issues (Dec '16)||Dec '16||Mattsc15||1|
Find what you want!
Search Cardiology Forum Now
Copyright © 2017 Topix LLC